Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» 2 Reasons Why Eli Lilly's Mounjaro Might Beat Novo Nordisk's Ozempic, and 2 Reasons Why It Might Not
2 Reasons Why Eli Lilly's Mounjaro Might Beat Novo Nordisk's Ozempic, and 2 Reasons Why It Might Not
2 Reasons Why Eli Lilly's Mounjaro Might Beat Novo Nordisk's Ozempic, and 2 Reasons Why It Might Not
Submitted by
admin
on October 6, 2023 - 10:08am
Source:
Motley Fool
News Tags:
Novo Nordisk
Eli Lilly
Ozempic
Mounjaro
diabetes
weight loss
Headline:
2 Reasons Why Eli Lilly's Mounjaro Might Beat Novo Nordisk's Ozempic, and 2 Reasons Why It Might Not
snippet:
Ozempic and Mounjaro are key drugs for Novo Nordisk and Eli Lilly, respectively.
Both treat most of the same conditions, and both are major drivers of earnings.
The fight for market share of a valuable health segment is just getting started.
Do Not Allow Advertisers to Use My Personal information
